| Literature DB >> 33967809 |
Shengnan Liao1, Wang Yue1, Shuning Cai1, Quan Tang1, Weitong Lu1, Lingxiao Huang2, Tingting Qi2,3, Jinfeng Liao1.
Abstract
Cancer is a life-threatening disease, and there is a significant need for novel technologies to treat cancer with an effective outcome and low toxicity. Photothermal therapy (PTT) is a noninvasive therapeutic tool that transports nanomaterials into tumors, absorbing light energy and converting it into heat, thus killing tumor cells. Gold nanorods (GNRs) have attracted widespread attention in recent years due to their unique optical and electronic properties and potential applications in biological imaging, molecular detection, and drug delivery, especially in the PTT of cancer and other diseases. This review summarizes the recent progress in the synthesis methods and surface functionalization of GNRs for PTT. The current major synthetic methods of GNRs and recently improved measures to reduce toxicity, increase yield, and control particle size and shape are first introduced, followed by various surface functionalization approaches to construct a controlled drug release system, increase cell uptake, and improve pharmacokinetics and tumor-targeting effect, thus enhancing the photothermal effect of killing the tumor. Finally, a brief outlook for the future development of GNRs modification and functionalization in PTT is proposed.Entities:
Keywords: Cancer; Gold nanorods; Localized tumor treatment; Nanomaterials; Photothermal therapy
Year: 2021 PMID: 33967809 PMCID: PMC8100678 DOI: 10.3389/fphar.2021.664123
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Optical properties of gold nanorods. (A) GNRs have two surface plasmon resonance bands: one transverse and the other longitudinal. The longitudinal one varies with the aspect ratios (AR). Aspect Ratio = l/d. (B) TEM images and UV−vis−NIR extinction spectra of GNRs with AR 1.5–3.5, aspect ratios are indicated above the absorbance spectrum of each sample. Scale bars are 100 nm. (C) Schematic representation of transverse and longitudinal plasmon absorbances in GNRs (Lohse and Murphy 2013).
Summaries of synthesis methods of gold nanorods and their improvements.
| Synthesis methods | Goals of improvements | Specific methods | References | |
|---|---|---|---|---|
| Seed-mediated growth method | Reduce toxicity | A simple “one-pot method” was proposed which adds sodium borohydride to remove CTAB. |
| |
| Replacing ascorbic acid with dopamine |
| |||
| Using a less toxic surfactant, dodecyl dimethyl ammonium bromide (C12EDMAB) as an alternative |
| |||
| Synthesizing hollow GNRs with nontoxic modifiers |
| |||
| Control the AR | Increasing the concentration of silver nitrate for higher AR |
| ||
| Adjusting the reaction time |
| |||
| Adjusting the temperature |
| |||
| Adjusting the pH |
| |||
| Adjusting the concentration of the ascorbic acid |
| |||
| Adjusting the amount of the seeds |
| |||
| Adjusting the concentration of the CTAB. |
| |||
| Using 3-aminophenol as the reducing agent |
| |||
| Adding HCl |
| |||
| Adding bioadditives like glutathione or small thiolated molecules |
| |||
| Thermal reshaping |
| |||
| Control the size | Adjusting the concentration of seeds added in the growth solution | ( | ||
| Control the end shape | Longer cylindrical-shaped GNRs were synthesized by adding HCl and dog-bone shaped GNRs were fabricated in the group without HCl |
| ||
| The number of anions rather than the pH altered by HCl chiefly determines the end shape |
| |||
| Improve the monodispersity | Replacing the ascorbic acid with hydroquinone |
| ||
| Replacing the ascorbic acid with 3-aminophenol | ( | |||
| Replacing the ascorbic acid with pyrogallol |
| |||
| Replacing the ascorbic acid with dopamine |
| |||
| Improve the reproducibility | Continuous agitation at a constant temperature of 30°C |
| ||
| Using CTAB and n-decanol as surfactants Seperating the symmetry breaking and the seeded growth process |
| |||
| Secondary growth of GNRs |
| |||
| Controlled etching |
| |||
| Improve the yield | Increasing HAuCl4 concentration and slowly adding ascorbic acid | ( | ||
| Simultaneously increasing the concentration of seeds and reactants |
| |||
| Adding ascorbic acid to GNRs solution continuously |
| |||
| Replacing ascorbic acid with hydroquinone |
| |||
| Using hydroquinone as a reducing agent |
| |||
| Using 3-aminophenol as the reductant |
| |||
| Introducing sliver ion for high yields of short GNRs |
| |||
| Using freshly prepared silver nitrate and ascorbic acid solutions |
| |||
| Using different concentrations of GSSG at 30 min of reaction |
| |||
| Raising pH |
| |||
| Asymmetric-flow field flow fractionation (A4F) |
| |||
| Introducing the right proportion of seeds, Au3+ ion, ascorbic acid, and CTAB | ( | |||
| Seedless method | Improve morphology | Adjusting the concentrations of CTAB and sodium oleate |
| |
| Promote the anisotropic growth | Introducing a weaker reducing agent (hydroquinone), with template modification |
| ||
| Introducing a weaker reducing agent (resveratrol) |
| |||
| Improve the yield | Increasing the concentration of the gold precursor solution |
| ||
Summaries of functionalization of gold nanorods aimed at specific procedures of photothermal therapy.
| The specific procedure | Materials | Therapy type | Cell line | Cancer model | References |
|---|---|---|---|---|---|
| Improve cellular uptake efficiency | PEG-coated and DNA-coated GNRs | - | - | - |
|
| CTAB-coated GNRs, polystyrene sulfonate (PSS)-coated GNRs, and poly (diallyldimethyl ammonium chloride)(PDDAC)-coated GNRs | - | - | - |
| |
| Citrate acid stabilized GNRs and transferrin-coated GNRs | - | HeLa | - |
| |
| GNRs that feature cationic ligands with diverse headgroups | - | HeLa | - |
| |
| GNRs functionalized with hairpin DNA (hpDNA) | - | HeLa | - |
| |
| Folate-functionalized silica-coated GNRs | - | HepG2 | Rabbit liver VX-2 tumor |
| |
| Neutral and cationic PEG-decorated GNRs | - | - | - |
| |
| Anionic poly acrylic acid (PAA)-decorated GNRs and bovine serum albumin (BSA)-coated GNRs | |||||
| Herceptin–GNRs complexes | Chemotherapy | SK-BR-3 | - |
| |
| PEGylated GNRs | - | HeLa | - |
| |
| Phospholipid-PEG-GNRs | Chemotherapy | MCF-7 | - |
| |
| T47D | |||||
| Chitosan-capped GNRs | - | HepG2 | - |
| |
| CTAB-coated GNRs and polyelectrolyte-coated GNRs | Chemotherapy | MCF-7 | - |
| |
| Polyelectrolyte-coated GNRs and PEG-GNRs | - | - | - |
| |
| GNRs coated with (16-mercaptohexadecyl) trimethylammonium bromide (MTABGNRs) | PTT | DU145 | - |
| |
| HeLa | |||||
| TRAMP-C2 | |||||
| GNRs coated with CTAB, polyoxyethylene cetyl ether, oligofectamine, and phosphatidylserine | - | - | - |
| |
| CTAB capped gold nanorods, GNRs coated with polyacrylic acid (PAA) and poly (allylamine) hydrochloride (PAH) | - | HT-29 | - |
| |
| Albumin-coated and fibrinogen-coated GNRs | PTT | MCF-7 | - |
| |
| Fetal bovine serum (FBS)-coated and non-fbs-coated GNRs | - | SMCC-7721 | - |
| |
| GES-1 | |||||
| 4T1 | |||||
| GNRs coated with two different densities of SH-PEG | - | - | - |
| |
| GNRs conjugated with methylated poly (ethyleneglycol) chains bearing a terminal amine (mPEG-NH2) | PTT | KB | - |
| |
| PSS-, PEG-, mSiO2-, dSiO2-, TiO2-coated GNRs | PTT | HepG2 | - |
| |
| HT-29 | |||||
| U-87MG | |||||
| PC-3 | |||||
| MDA-MB-231 | |||||
| Arg gly asp (RGD) peptide-functionalized GNRs | PTT | HSC-3 | - |
| |
| PEG coated GNRs treated with folic acid and loaded with mitoxantrone | Chemotherapy | Hela | - |
| |
| PTT | C6 | ||||
| Short GNRs functionalized with folic acid (FA) and 8-mercaptooctanoic acid (MOA) or 11-mercaptoundecanoic acid (MDA) and loaded with paclitaxel (PCT) | Chemotherapy PTT | MDA-MB-231 MCF-7 | - |
| |
| Human serum albumin/GNRs/doxorubicin/plga | Chemotherapy | CT26 | Murine colon cancer |
| |
| PTT | |||||
| Hybrid albumin nanoparticles encapsulating small GNRs | PTT | N2a | Glioblastoma N2a tumor-bearing mice |
| |
| Dual-peptide labeled GNRs | PTT | 6606PDA | - |
| |
| Poly (diallyldimethylammonium chloride)-coated GNRs | - | - | - |
| |
| Reduce the damage to vascular endothelium and systemic toxicity | Multifunctional PEG-b-polypeptide-decorated GNRs | Chemotherapy-PTT | MCF-7 | Breast cancer |
|
| Arg-gly-asp (RGD) peptide-functionalized GNRs | PTT | HSC | - |
| |
| GNRs linked with rifampicin | PTT | T-U686 | Head and neck squamous cell carcinoma (HNSCC) |
| |
| Albumin nanoparticles functionalized with folic acid loaded with GNRs and doxorubicin | Chemotherapy-PTT | HeLa | Human cervical cancer |
| |
| Small GNRs-loaded hybrid albumin nanoparticles | PTT | N2a | Glioblastoma |
| |
| Prolong the blood circulation time | GNRs coated with a zwitterionic stealth peptide | PTT | HepG2 | Human liver cancer |
|
| Polysarcosine brush stabilized GNRs | PTT | A549 | Human lung cancer |
| |
| GNRs modified with folic acid-conjugated block copolymers and Chlorine6(Ce6) | PDT-PTT | MCF-7and A549 | - |
| |
| Ultrasmall GNRs coated with PEG and PLGA | PTT | U87MG | Human glioma |
| |
| Hyaluronic acid-functionalized GNRs | PTT | B16F10.9 | Murine melanomas | ( | |
| GNRs-loaded thermosensitive liposome-encapsulated ganoderic acid | Chemotherapy-PTT | MCF-7 | Human breast cancer |
| |
| Enhance passive targeting (EPR effect) | 64Cu-labeled PEGylated | - | U87MG | Human glioma |
|
| GNRs with different volumes and aspect ratios | |||||
| A dissociable plasmonic vesicle with ultrasmall size (≈60 nm) assembled from small amphiphilic GNRs (≈8 × 2 nm) coated with PEG and PLGA | PTT | U87MG | Human glioma |
| |
| A nanoplatform by assembling gold nanorods (GNRs) on the surface of a triangular DNA-origami structure | PTT | 4T1 | Breast cancer |
| |
| Self-assembled DNA origami-GNRs complex | PTT | MCF-7 | Breast cancer |
| |
| GNRs coated with thiolated PEG | - | - | - |
| |
| DOX and GNRs co-loaded polymersomes modified by mPEG-PCL copolymer | PTT-chemotherapy | C26 | Mouse colon cancer |
| |
| GNRs coated with an enzyme responsive zwitterionic stealth peptide coating consists of a cell penetrating Tat sequence, an MMP-9 cleavable sequence, and a zwitterionic antifouling sequence | PTT | HepG2 | Human liver cancer |
| |
| Enhance active targeting aimed at the tumor-specific receptors | GNRs functionalized with folic acid and 8-mercaptooctanoic acid (MOA) or 11-mercaptoundecanoic acid (MDA) and loaded with paclitaxel | PTT-chemotherapy | MDA-MB-231/MCF-7 | Breast adenocarcinoma |
|
| GNRs functionalized with folic acid and loaded with IDO small interfering RNA | PTT-immunotherapy | - | LLC (lewis lung cancer) |
| |
| Arg–Gly–Asp (RGD) peptide-functionalized PEGylated | PTT | HSC-3 | Human oral squamous cell carcinoma |
| |
| GNRs | |||||
| GNRs functionalized with PEG and arg–Gly–Asp (RGD) peptides | PTT | HeLa/MCF-7 | Human cervical cancer/Breast cancer |
| |
| GNRs combined with 15-polypeptide | PTT | SKOV-3 | Ovarian cancer |
| |
| GNRs linked with anti-cd11b antibodies-decorated NPs | PTT | - | - |
| |
| Anti-EGFR antibody-conjugated GNRs | PTT | MDA-MB-231 | TNBC (triple negative breast cancer) |
| |
| Sialic acid (SA)-imprinted GNRs | PTT | HepG-2 | Human hepatoma carcinoma |
| |
| Hybrid albumin nanoparticles encapsulating small GNRs | PTT | N2a | Glioblastoma |
| |
| GNRs/DOX/PLGA nanocomplexes coated with human serum albumin (HSA) | PTT-chemotherapy | CT26/MCF7/MCF7-ADR | Mouse colon cancer/Human breast cancer/Multidrug-resistant human breast cancer |
| |
| Enhance active targeting aimed at the tumor-specific pathophysiological conditions | DOX-loaded gold-core silica shell nanorods with salicylic acid and NaHCO3 loaded poly (lactic-co-glycolic acid) based microparticles | PTT-chemotherapy | HeLa | Human cervical cancer |
|
| A nano-cluster prepared by self-assembling of GNRs conjugated with DOX and amphiphilic poly (curcumin-co-dithiodipropionic acid)-b-biotinylated poly (ethylene glycol) | PTT-chemotherapy | MCF7/MCF7-ADR | Human breast cancer/Multidrug-resistant human breast cancer |
| |
| Ce6-PEG-GNRs concerning hydrazone bond | PTT-PDT | HeLa | Human cervical carcinoma |
| |
| A new nanoconstruct composed of GNRs conjugated to carbonic anhydrase IX (CAIX) antibody | PTT | HT29 | Human colon adenocarcinoma |
| |
| GNRs coated with an enzymeresponsive zwitterionic stealth peptide coating consists of a cellpenetrating Tat sequence, an MMP-9 cleavable sequence, and a zwitterionic antifouling sequence | PTT | HepG2 | Human liver cancer |
| |
| A protein-free collagen nanosweeper, triphenylphosphonium bromide (TPP) coated and S-nitrosothiols loaded mini-sized Au@silica nanorod | PTT | HeLa/4T-1/MCF-7 | Human cervical cancer/Breast cancer |
| |
| GNRs functionalized with hyaluronic acid (HA) bearing pendant hydrazide and thiol groups via Au-S bonds and conjugated with 5-aminolevulinic acid (ALA), Cy7.5 and anti-HER2 antibody | PTT-PDT | MCF-7 | Breast cancer |
| |
| Disulfiram- GNRs integrate | PTT-chemotherapy | MCF-7 | Breast cancer |
| |
| Enhance cell-mediated targeting | Human CIK cells loaded with silica-coated GNRs | PTT-immunotherapy | MGC803 | Gastric cancer |
|
| GNRs-loaded platelets | PTT | CAL27 | HNSCC (head and neck squamous cell carcinoma) |
| |
| Macrophages loaded with GNRs and DOX-LPs | PTT-chemotherapy | 4T1 | Breast cancer |
| |
| Macrophage-loaded Anionic-GNRs | PTT | 4T1 | Breast cancer |
| |
| Human induced pluripotent stem cells loaded with GNRs @SiO2@CXCR4 nanoparticles | PTT | MGC803 | Gastric cancer |
| |
| Human induced pluripotent stem cells loaded with GNRs @SiO2@CXCR4 nanoparticles which were pre-treated with mitomycinC (MMC) | PTT | MGC803 | Gastric cancer |
| |
| Enhance homologous targeting (cancer cell membrane-mediated targeting) | Cancer cell membrane-coated GNRs | PTT-radiotherapy | KB | Human oral squamous cancer |
|
| Cancer cell membrane loaded with a biodegradable nanogel crosslinked by cisplatin (CDDP) and functionalized with GNRs and DOX | PTT-chemotherapy | 4T1 | Breast cancer |
| |
| Improve the tumor killing effect | Chitosan-conjugated, pluronic-based nanocarriers with GNRs | PTT | SCC7 | Squamous carcinoma |
|
| GNRs and doxorubicin co-loaded polymersomes | PTT and chemotherapy | C26 | Colon cancer |
| |
| GNRs/chlorin e6(Ce6) loaded stem cell system | PTT and PDT | CT26 | Colon cancer |
| |
| Zinc phthalocyanine loaded GNRs | PTT and PDT | Hela | Cervical cancer |
| |
| MCF-7 | Breast cancer | ||||
| GNRs、folic acid、Ido small interfering RNA nanocomplex | PTT and immunotherapy | LLC | Lung cancer |
| |
| Pyrene-aspirin loaded GNRs | PTT and anti-inflammatory therapy | 4T1 | Breast cancer |
| |
| Construct a pH/NIR triggered drug release system | A novel pH sensitive targeted polysaccharide-GNRs conjugate | Photothermal-chemotherapy | MCF-7 | Breast cancer |
|
| GNRs/mSiO2 combined with PH responsive polyhistidine | Photothermal-chemotherapy | SW620 | Human colon cancer |
| |
| Hyaluronic acid-functionalized GNRs | Photothermal-chemotherapy | MCF-7 | Breast cancer |
| |
| GNRs/hydrogel core/shell nanospheres | Photothermal-chemotherapy | PC-3 | Human prostate cancer |
| |
| Construct a redox/pH/NIR triggered drug release system | GNRs-based complexes containing hydrazine and disulfide bonds | Photothermal-chemotherapy | MCF-7 | Breast cancer |
|
| Disulfiram-GNRs | Photothermal-chemotherapy | MCF-7 | Breast cancer |
| |
| PH/Redox responsive core cross-linked nanoparticles from thiolated carboxymethyl chitosan | Photothermal-chemotherapy | HeLa | Human cervical cancer |
| |
| GNRs and docetaxel based nanoparticles coated with ultra-thin MnO2 nano-film | Photothermal-chemotherapy | MCF-7 | Breast cancer |
|
FIGURE 2Illustration of several factors affecting the cellular uptake of GNRs.
FIGURE 3Two mechanisms of cellular uptake of gold nanorods: receptor-mediated endocytosis and caveolae dependent pinocytosis. Long nanorods pre-align to the cell membrane almost parallelly, then rotate by around 90° to enter the cell, while short nanorods can directly be entrapped by cells without rotation.
FIGURE 4Illustration of recent improvements on the tumor accumulation of GNRs.
FIGURE 5Optoacoustic evaluation of DNA-Nanostructure-Gold-Nanorod Hybrids which achieve better accumulation in tumor sites than pure GNRs. (A) The gold distribution (hot scale, a,c) and the corresponding oxygen-saturation maps (green to red scale, b,d) before intravenous injection of GNRs and GNRs with DNA nanostructures (D-GNRs) in 4T1-tumor-bearing mice. (B) GNRs and D-GNRs distribution (hot scale) at several time points including 5 min (a,f), 1 h (b,g), 3 h (c,h), 7 h (d,i), 24 h (e,j) after intravenous injection in 4T1-tumor-bearing mice (dashed outlined) overlayed on an optoacoustic image acquired at a single illumination wavelength (710 nm, gray scale). Scale bar = 5 mm. (C) 3D rendering the optoacoustic images in the cancerous regions on 4T1-tumor-bearing mice 24 h postinjection of the GNRs (a, hot scale) and D-GNRs (b, hot scale), overlayed on single wavelength images (c,d, 710 nm, gray scale). Scale bar = 5 mm. (D) Contrast ratio between the tumor and the region of back muscles extracted from the images for GNRs (blue) and D-GNRs (red). A section of the back muscle (indicated by the white arrows) is outlined in the initial single wavelength image (Du et al., 2016b).
FIGURE 6The preparation and properties of hypoxia-targeted GNRs. (A) The preparation of hypoxia-targeted GNRs. The conjugation of GNRs with anti-CAIX antibody via bi-functional crosslinker. (B) Comparison of gold content in tissues by Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) 24 h after intravenous administration of targeted (GNRs/anti-CAIX) and untargeted (GNRs-PEG) GNRs in HT29-tumor-bearing mice (n = 4 for both groups). The uptake of GNRs/anti-CAIX was significantly higher than GNRs-PEG in xenograft tumor (*p < 0.05). The biodistribution in other organs was similar for both groups except higher uptake in the kidney for GNRs/anti-CAIX. (C) Photothermal ablation via near infrared irradiation of HT29 tumors 24 h after tail-vein injection of saline (n = 3), GNRs-PEG (n = 5, OD = 20) or GNRs/anti-CAIX (n = 7, OD = 20). Images of representative mice in each group prior to treatment, one day after treatment, and 16 days after treatment. Tumor volume plotted over time for all three groups. (D) No tumor regression in the saline-treated group; regression but recurrence of tumor in the GNRs-PEG treated group; and complete tumor regression in the GNRs/anti-CAIX treated group (Chen et al., 2018a). (Hypoxia-targeted gold nanorods for cancer photothermal therapy, https://creativecommons.org/licenses/by/3.0/).
FIGURE 7Combination of photothermal therapy and other therapies. (A) The combination of photothermal and chemotherapy using GNRs and doxorubicin co-loaded polymersomes (P-GNRs-DOX) irradiated by 808 nm laser. (Combined Cancer Photothermal-Chemotherapy Based on Doxorubicin/Gold Nanorod-Loaded Polymersomes, http://creativecommons.org/licenses/by-nc-nd/3.0/). (B) The combination of photothermal and photodynamic therapy using AuNR-PEG-PEI (APP)/chlorin e6 (Ce6)-loaded adipose-derived stem cell (ADSC) system irradiated by 808 nm light for PDT and 660 nm light for PTT. (Chuang et al., 2020).